Skip To Main Content
Matthew E. Ehrlich on Muck Rack

Matthew E. Ehrlich

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Matthew E. Ehrlich’s profile

Articles by Matthew E. Ehrlich

Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus

|
By Matthew E. Ehrlich, Haolin Xu, Andrzej S. Kosinski, Adrian F. Hernandez, Adrian Hernandez Verified
| AHA/ASA Journals
Originally publishedhttps://doi.org/10.1161/STROKEAHA.118.024172Stroke. ;0 Abstract Background and Purpose— Acute ischemic stroke patients with history of prior ischemic stroke plus concomitant diabetes mellitus (DM) were excluded from the ECASS III trial (European Cooperative Acute Stroke Study) because of safety concerns. However, there are few data on use of intravenous tissue-type plasminogen activator and symptomatic intracerebral hemorrhage or outcomes in this population.
Open in Who Shared Issue with article?

Response by Ehrlich et al to Letter Regarding Article, “Safety of Computed Tomographic Angiography in the Evaluation of Patients With Acute Stroke: A Single-Center Experience” | Stroke

|
By Matthew E. Ehrlich, Bradford B. Worrall, Andrew M. Southerland
| stroke.ahajournals.org
We appreciate Drs Wu, Tu, and Malhotra’s well-informed comments on our article, “Safety of Computed Tomographic Angiography in the Evaluation of Patients With Acute Stroke: A Single-Center Experience,” and the opportunity to respond.
Open in Who Shared Issue with article?

Safety of Computed Tomographic Angiography in the Evaluation of Patients With Acute Stroke

|
By Heather Turner, Max Wintermark, Matthew E. Ehrlich, Lillian J. Currie
| stroke.ahajournals.org
Background and Purpose—Noncontrasted head computed tomography (NCHCT) has long been the standard of care for acute stroke imaging. New guidelines recommending advanced vascular imaging to identify eligible patients for endovascular therapy have renewed safety concerns on the use of contrast in the emergent setting without laboratory confirmation of renal function.
Open in Who Shared Issue with article?
Show More